Week 7b: Comprehensive Study Guide to Monoamine Oxidase Inhibitors (MAOIs)

Historical Discovery and Context of Monoamine Oxidase Inhibitors

  • Monoamine oxidase inhibitors (MAOIs) were discovered accidentally during medical research into tuberculosis treatments.

  • The agent I niazi (Iproniazid) was used for tuberculosis patients when researchers noted that patients with depression experienced significant mood improvement.

  • Although this specific agent was eventually removed from the market due to concerns regarding liver damage, it served as the progenitor for the antidepressant class of MAOIs.

  • MAOI use later expanded into the treatment of Parkinson's disease.

  • Use of this class diminished significantly following the introduction of tricyclic antidepressants (TCAs), primarily due to significant concerns regarding drug-drug and drug-food interactions.

Mechanism of Action: MAO-A and MAO-B Enzymes

  • There are two primary monoamine oxidase enzymes: MAO-A and MAO-B.

  • Location:

    • Both MAO-A and MAO-B are located in the brain.

    • MAO-A is additionally located in the gut, which is critical for understanding food-based interactions.

  • Neurotransmitter Processing:

    • MAO-A: Processes dopamine, norepinephrine, serotonin, and tyramine. It preferentially utilizes serotonin and norepinephrine. Only at very high concentrations do these neurotransmitters cross over to be processed by MAO-B.

    • MAO-B: Primarily processes dopamine, tyramine, and phenylethylamine. It also processes certain toxins and various other compounds.

  • Targeting:

    • For the treatment of depression, MAO-A is the primary target.

    • MAO-B has historically been the target for treating Parkinson's disease.

Classification and Characteristics of MAOI Agents

  • Prescriber Familiarity: A survey conducted approximately 66 to 77 years ago indicated that less than 20%20\% of prescribers (physicians, nurse practitioners, nurses, and pharmacists) had ever used MAOIs, and about 75%75\% felt uncomfortable using them due to interaction risks.

  • Non-selective Irreversible MAOIs: Include ISO carbox (Isocarboxazid), phenyl zine (Phenelzine), and tranylcypromine.

    • These agents bind to both MAO-A and MAO-B enzymes.

    • They are irreversible, meaning they permanently deactivate the enzyme. The body must synthesize new enzymes, a process that typically takes between 22 and 44 weeks.

  • Selective MAOIs: Egine (Selegiline) is the primary example.

    • It is more selective for the MAO-B enzyme at low doses but can inhibit MAO-A as well.

    • It is also irreversible.

    • Selegiline is available as a transdermal patch, which bypasses initial gut enzyme inhibition at certain doses.

Medication and Food Interaction Risks

  • Mechanism of Danger: Because MAOIs inhibit the breakdown of monoamines, they cause higher concentrations of dopamine, norepinephrine, and serotonin. Adding other agents that further increase these levels can lead to fatal effects.

  • High-Profile Risks:

    • Hypertensive Crisis: Caused by excess norepinephrine.

    • Serotonin Syndrome: Caused by excess serotonin.

  • Washout Periods: It is essential to allow current medications to clear the system before starting MAOIs, or allowing MAOIs to clear before starting a new agent. Fluoxetine is a notable exception needing a longer washout due to its extended half-life.

  • Contraindicated Medications:

    • Decongestants: Pseudoephedrine and phenyl rine (phenylephrine). Short-term use of specific non-extended release versions might be safe under supervision, but chronic use is highly problematic. Intranasal topical decongestants are the safest alternative but should not be used for more than 7272 hours.

    • Stimulants: Increase available norepinephrine; however, selegiline metabolites are stimulants, and MAOIs are occasionally used with stimulants in highly monitored, refractory depression cases.

    • Antidepressants: SNRIs (serotonin-norepinephrine reuptake inhibitors) and TCAs (tricyclic antidepressants).

    • Cough and Cold Preparations: Dextromethorphan can inhibit the serotonin transporter, leading to risk when combined with MAOIs.

    • Opioids: Meperidine and tramadol can increase serotonin and potentially cause fatal serotonin syndrome.

Dietary Tyramine and the "Cheese Effect"

  • Tyramine is an amino acid in food that stimulates the release of norepinephrine.

  • In healthy adults, 40 mg40\,mg to 400 mg400\,mg of tyramine is tolerated with minimal blood pressure changes because gut MAO-A enzymes break it down.

  • On non-selective MAOIs, gut enzymes are inhibited. Dietary studies show as little as 10 mg10\,mg of dietary tyramine can significantly increase blood pressure from baseline in these patients.

  • High Tyramine Foods to Avoid:

    • Aged Cheeses: Go Zola (Gorgonzola) and blue cheese.

    • Processed Meats: Dried, aged, smoked, or cured meats (e.g., pepperoni, summer sausage, salami).

    • Fermented/Processed Items: Sauerkraut, kimchi, tofu, soy products, and Marmite/yeast extracts.

    • Vegetables: Fava beans.

    • Beverages: Tap or unpasteurized beer, and red wines like Chianti.

Efficacy Data and Clinical Comparisons

  • A meta-analysis of randomized controlled trials (1212 for ISO carbox, 1414 for phenelzine, and 77 for pranal sipper/tranylcypromine) demonstrated significant results:

    • Response Rate: Defined as a 50%50\% or greater reduction in the Hamilton Depression Rating score or a Clinical Global Impression (CGI) score of 11 or 22 (much/very much improved).

    • Both inpatient and outpatient response rates hovered around 50%50\%.

  • ISO Carbox: Found to be less effective than some TCAs (like ermine/imipramine or amitriptyline) in inpatients but showed better efficacy in outpatient trials of longer duration.

  • Fennel Z (Phenelzine):

    • For atypical depression, daily doses of 6060 to 90 mg90\,mg were found to be more effective than imipramine.

    • At lower doses or in non-atypical depression, TCAs were superior.

  • Tranylcypromine: Showed significant improvement for inpatients, with efficacy similar to TCAs for patients with bipolar depression.

  • Selegiline Transdermal Patch:

    • At the fixed 6 mg6\,mg dose, there is no requirement for dietary tyramine restrictions as it does not seem to interact with gut MAO-A.

    • At flexible doses of 9 mg9\,mg or 12 mg12\,mg per 2424 hours, dietary restrictions are required.

    • Clinical trials showed a significant least square mean change of approximately 99 to 1010 points on the Hamilton Depression Rating scale over an 88 week period compared to placebo.

Tolerability and Emerging Therapeutic Roles

  • General Tolerability: While risks for hypertensive crisis and serotonin syndrome exist, MAOIs are otherwise well-tolerated. Common side effects include:

    • Initial anxiety and dry mouth.

    • Gastrointestinal issues, specifically constipation.

    • Sleep changes: Primarily insomnia, though some drowsiness is reported.

  • Comparison to TCAs: Meta-analysis data showed significantly more dropouts due to tolerability issues with TCAs than with MAOIs.

  • Neuroprotection: Interest in MAOIs is resurging because MAO enzymes create radical oxygen species (like hydrogen peroxide) and toxins as they break down monoamines. Blocking these enzymes may prevent neurodegeneration.

  • Specific Future Applications:

    • Brain-Derived Neurotrophic Factor (BDNF): Animal studies show MAOIs increase the synthesis of BDNF, which supports neuron health.

    • Dementia and Alzheimer's: Potential for preventing progression of cognitive impairment by reducing oxidative species.

    • Heart Failure: MAO enzymes are upregulated in heart failure and produce reactive oxygen species that attack the myocardium. MAOIs may protect heart tissue.

    • Inflammatory Conditions: In conditions like multiple sclerosis, rheumatoid arthritis, Crohn's disease, and renal disease, high IGA levels and tumor necrosis factor (TNF) alpha are present. High levels of monoamines contribute to the inflammatory cascade; MAOIs have been shown to lower TNF alpha levels.